天津医药

• 短篇论著 •    

尤瑞克林治疗急性脑梗死的疗效观察

王雪松1,臧大维2,左宪华3,任晓莉3   

  1. 1. 天津市第一中心医院
    2. 00
    3. 天津市第一中心医院神经内科
  • 收稿日期:2009-12-16 修回日期:2010-01-08 出版日期:2010-04-15 发布日期:2010-04-15
  • 通讯作者: 王雪松

  • Received:2009-12-16 Revised:2010-01-08 Published:2010-04-15 Online:2010-04-15

PDF (PC)

848

摘要： 【摘要】　目的:探讨尤瑞克林治疗急性脑梗死的疗效。方法:对我院近1年72例发病48小时内的急性脑梗死患者，随机分为治疗组及对照组各36例。分别在治疗前，治疗后1周，治疗后2周评估其NIHSS评分及ADL评分，并进行临床疗效评估。结果:治疗后2周, 治疗组在NIHSS评分及ADL评分上均优于对照组( P < 0. 05) 。治疗组总有效率为88.89%，对照组总有效率为66.67%，两组比较差异有统计学意义( P < 0. 05)。结论:尤瑞克林能有效改善急性脑梗死患者的神经功能缺损和日常生活能力，且无明显不良反应，值得临床推广使用。

关键词: 　尤瑞克林, 急性脑梗死, 治疗

Abstract: 【Abstract】 Objective : The efficacy of Urinary Kallidinogenase in treating patients with acute cerebral infarction have been observed. Methods : 72 cases of our hospital nearly a year within 48 hours of onset of acute cerebral infarction were randomly divided into treatment group and control group of 36 cases. Respectively, before treatment and after treatment, 1 week, 2 weeks after treatment to assess their NIHSS score and ADL score, and clinical efficacy evaluation. Results: After 2 weeks, the treatment group in the NIHSS score and ADL score is superior to the control group (P <0. 05). The treatment group, the total efficiency of 88.89% ；in the control group, the total efficiency of 66.67%, the difference was statistically significant (P <0. 05). Conclusion: Kallidinogenase injection can effectively improve the acute cerebral infarction in patients with neurologic impairment and activities of daily living, and no significant adverse reactions, it is worth for clinical use.

Key words: 　kallidinogenase, acute cerebral infarction, treatment